Significance of split-dose cisplatin-based neoadjuvant chemotherapy followed by robotic-assisted radical cystectomy for muscle invasive bladder cancer.

ABSTRACT:

Background

Although cisplatin is essential for neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC), good renal function is a prerequisite for those patients receiving NAC. However, patients with normal renal function may experience nephrotoxicity after cisplatin administration. We investigated the safety and efficacy of a split-dose regimen of gemcitabine and cisplatin (split-dose GC) in MIBC patients with normal renal function.

Methods

This retrospective study included 45 patients with MIBC who received standard GC, split-dose GC, or gemcitabine and carboplatin (GCarbo) as a NAC and subsequently underwent robot-assisted radical cystectomy. The efficacy and safety of two cycles split-dose GC were compared with those of other regimens.

Res

SUBMITTER: Nakane K 

PROVIDER: S-EPMC11986500 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature